Chartwell Investment Partners LLC Purchases Shares of 17,116 BioTelemetry Inc (BEAT)

Share on StockTwits

Chartwell Investment Partners LLC purchased a new position in shares of BioTelemetry Inc (NASDAQ:BEAT) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,116 shares of the medical research company’s stock, valued at approximately $1,072,000.

Several other large investors also recently made changes to their positions in BEAT. Deutsche Bank AG increased its holdings in shares of BioTelemetry by 119.7% during the fourth quarter. Deutsche Bank AG now owns 310,751 shares of the medical research company’s stock worth $18,556,000 after buying an additional 169,306 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of BioTelemetry by 213.4% during the fourth quarter. Legal & General Group Plc now owns 219,499 shares of the medical research company’s stock worth $13,054,000 after buying an additional 149,453 shares in the last quarter. BlackRock Inc. increased its holdings in shares of BioTelemetry by 2.7% during the fourth quarter. BlackRock Inc. now owns 5,092,773 shares of the medical research company’s stock worth $304,141,000 after buying an additional 134,956 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of BioTelemetry by 332.4% during the third quarter. Point72 Asset Management L.P. now owns 92,100 shares of the medical research company’s stock worth $5,936,000 after buying an additional 70,800 shares in the last quarter. Finally, Vanguard Group Inc increased its holdings in shares of BioTelemetry by 2.8% during the third quarter. Vanguard Group Inc now owns 1,900,117 shares of the medical research company’s stock worth $122,462,000 after buying an additional 52,363 shares in the last quarter. Institutional investors own 88.51% of the company’s stock.

NASDAQ BEAT opened at $58.12 on Wednesday. The firm has a market capitalization of $2.00 billion, a P/E ratio of 29.96 and a beta of 1.44. BioTelemetry Inc has a twelve month low of $32.65 and a twelve month high of $80.92. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Thursday, February 21st. The medical research company reported $0.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.13. The business had revenue of $103.60 million during the quarter, compared to the consensus estimate of $102.84 million. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. BioTelemetry’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.32 earnings per share. On average, sell-side analysts anticipate that BioTelemetry Inc will post 1.94 EPS for the current fiscal year.

BEAT has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $84.00 price target for the company in a report on Thursday, February 28th. BidaskClub downgraded BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. Lake Street Capital set a $90.00 price objective on BioTelemetry and gave the company a “buy” rating in a report on Friday, February 22nd. ValuEngine downgraded BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 23rd. Finally, Sidoti set a $95.00 price objective on BioTelemetry and gave the company a “buy” rating in a report on Tuesday, February 5th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $80.33.

In other BioTelemetry news, VP Heather C. Getz sold 93,383 shares of the company’s stock in a transaction on Tuesday, January 29th. The shares were sold at an average price of $70.06, for a total transaction of $6,542,412.98. Following the sale, the vice president now owns 119,085 shares of the company’s stock, valued at $8,343,095.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Heather C. Getz sold 8,236 shares of the company’s stock in a transaction on Thursday, January 17th. The shares were sold at an average price of $70.01, for a total transaction of $576,602.36. Following the sale, the vice president now directly owns 88,797 shares in the company, valued at approximately $6,216,677.97. The disclosure for this sale can be found here. Insiders sold 177,198 shares of company stock valued at $12,419,736 over the last 90 days. 6.50% of the stock is currently owned by company insiders.

WARNING: “Chartwell Investment Partners LLC Purchases Shares of 17,116 BioTelemetry Inc (BEAT)” was posted by Macon Daily and is owned by of Macon Daily. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://macondaily.com/2019/04/17/chartwell-investment-partners-llc-purchases-shares-of-17116-biotelemetry-inc-beat.html.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

See Also: What is insider trading?

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.